Similarly, compared with Tc1 cells, adoptively transferred tumor-specific Tc9 cells showed better antitumor activity (Supplemental Figure 2, G and K) and persistence in tumors and spleens (Figure 1, J and L, and Supplemental Figure 2, H, I, and L), and tumor-infiltrating and splenic Tc9 cells contained less lipid ROS (Figure 1, K and M, and Supplemental Figure 2, J and M) in both s.c. MC38-gp100 colon cancer and B16 lung metastatic models. This evidence concerns the gene PMEL and neoplasm.